---
title: Improve motor symptoms via glucose
nct_id: NCT05998772
status: RECRUITING
sponsor: University Hospital Schleswig-Holstein
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05998772"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05998772"
last_fetched: "2026-05-10T14:05:20.416Z"
source: "Parkinson's Pathways (curated)"
---
# Improve motor symptoms via glucose

**Goal (in five words):** Improve motor symptoms via glucose

**Official Title:** Influence of Glucose on Metabolism and Clinical Symptoms of Patients With Parkinson's Disease

**Trial ID:** [NCT05998772](https://clinicaltrials.gov/study/NCT05998772)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** University Hospital Schleswig-Holstein
- **Target Enrollment:** 50 participants
- **Start Date:** 2023-09-01
- **Completion Date:** 2025-12
- **Conditions:** Parkinson Disease, Nutritional and Metabolic Diseases, Sugar Intake
- **Interventions:** Oral Glucose Tolerance Test, Placebo Oral Glucose Tolerance Test
- **Intervention Types:** DIAGNOSTIC_TEST, OTHER

## Summary For Families

The goal is to see how a glucose challenge changes metabolism and short-term Parkinson's symptoms, and whether people who crave sweets react differently. Participants get an oral glucose tolerance test and a placebo version, so researchers can compare blood glucose and metabolic markers along with motor and nonmotor symptom changes after a sugary drink versus a non‑sugar control; participants pause their morning Parkinson meds to avoid confounding. The trial is looking for people aged 50 to 80 with Parkinson's at Hoehn and Yahr stage 1.5 to 3 who can give consent and can safely skip their morning antiparkinsonian meds. People with diabetes or prediabetes, pacemakers, or on medications that affect glucose metabolism are excluded.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosis of Parkinson's Disease, stage Hoehn \& Yahr 1.5-3
* Ability to pause antiparkinsonian medication in the morning without relevant impairment
* Capacity to give consent (determined in doubt by two independent neurologists, MOCA ≥18) and written informed consent.
* Patients are between 50 and 80 years of age, with exceptions for a maximum of 5 additional patients enrolled per group
* For stratification into patients with and without sweet craving, a 3-day dietary protocol should be completed once by the patients
* Group I: increased hunger for sweets.
* Group II: no increased hunger for sweets.

For the stratification into patients with and without increased hunger for sweets, participants are asked to answer the following questions:

1. Do you have sudden attacks of cravings for sweets?
2. Would you say that your consumption of sweet food has increased in recent years?
3. Would you describe your consumption of sugary food as increased or excessive?

If one of the questions is answered with yes, participants will be assigned to group I, if all questions are answered with no, participants will be assigned to group II.

Exclusion Criteria:

* Other significant neurological diseases primarily affecting the central nervous system (e.g., multiple sclerosis)
* Diagnosis of diabetes mellitus or prediabetes
* Use of medications that affect glucose metabolism, such as antidiabetics, glucocorticoids, ciclosporin, tacrolimus, sirolimus, beta-blockers, thiazide diuretics, beta-2 adrenoreceptor agonists, theophylline, Clozapine, olanzapine, paliperidone, quetiapine, risperidone, tricyclic antidepressants, mirtazapine, mianserin, carbamazepine, gabapentin, pregabalin, valproic acid, lithium, antiretroviral drugs, statins
* cardiac or brain pacemakers
```

## Locations (1)

- Department for Neurology, University of Kiel, Kiel, Germany _(54.3213, 10.1349)_
  - Eva Schäffer, Dr. — (CONTACT) — 004943150023983 — eva.schaeffer@uksh.de

## Central Contacts

- Eva Schäffer, MD — (CONTACT) — 004943150023983 — eva.schaeffer@uksh.de
- Julienne Haas, MD — (CONTACT) — julienne.haas@uksh.de

---

*Canonical: https://parkinsonspathways.com/trial/NCT05998772*  
*HTML version: https://parkinsonspathways.com/trial/NCT05998772*  
*Source data: https://clinicaltrials.gov/study/NCT05998772*